Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Alterations in sarcomere function modify the hyperplastic to hypertrophic transition phase of mammalian cardiomyocyte development
Benjamin R. Nixon, Alexandra F. Williams, Michael S. Glennon, Alejandro E. de Feria, Sara C. Sebag, H. Scott Baldwin, Jason R. Becker
Benjamin R. Nixon, Alexandra F. Williams, Michael S. Glennon, Alejandro E. de Feria, Sara C. Sebag, H. Scott Baldwin, Jason R. Becker
View: Text | PDF
Research Article Cardiology Development

Alterations in sarcomere function modify the hyperplastic to hypertrophic transition phase of mammalian cardiomyocyte development

  • Text
  • PDF
Abstract

It remains unclear how perturbations in cardiomyocyte sarcomere function alter postnatal heart development. We utilized murine models that allowed manipulation of cardiac myosin-binding protein C (MYBPC3) expression at critical stages of cardiac ontogeny to study the response of the postnatal heart to disrupted sarcomere function. We discovered that the hyperplastic to hypertrophic transition phase of mammalian heart development was altered in mice lacking MYBPC3 and this was the critical period for subsequent development of cardiomyopathy. Specifically, MYBPC3-null hearts developed evidence of increased cardiomyocyte endoreplication, which was accompanied by enhanced expression of cell cycle stimulatory cyclins and increased phosphorylation of retinoblastoma protein. Interestingly, this response was self-limited at later developmental time points by an upregulation of the cyclin-dependent kinase inhibitor p21. These results provide valuable insights into how alterations in sarcomere protein function modify postnatal heart development and highlight the potential for targeting cell cycle regulatory pathways to counteract cardiomyopathic stimuli.

Authors

Benjamin R. Nixon, Alexandra F. Williams, Michael S. Glennon, Alejandro E. de Feria, Sara C. Sebag, H. Scott Baldwin, Jason R. Becker

×

Figure 3

There is a narrow developmental period when cardiomyopathy can be reversed.

Options: View larger image (or click on image) Download as PowerPoint
There is a narrow developmental period when cardiomyopathy can be revers...
(A) Schematic illustration of MYBPC3 conditional reactivation (Null R-P7) mice administered tamoxifen at P7 and phenotyped at P25. (B) H&E–stained cross sections of control (Ctl), MYBPC3-null (Null), and Null R-P7 hearts. Scale bars: 1 mm. (C and D) P25 heart weight (HW) (C) and HW to tibia length ratio (HW/TL) (D) of Ctl (n = 13), Null (n = 11), and Null R-P7 (n = 4) mice. (E) Schematic illustration of MYBPC3 conditional reactivation (Null R-P30) mice administered tamoxifen at P30 and phenotyped at P60. (F) H&E–stained cross-sections of Ctl, Null, and Null R-P30 hearts. Scale bars: 1 mm. (G and H) P60 HW (G) and HW/TL (H) in Ctl (n = 7), Null (n = 5), and Null R-P30 (n = 4) mice. All results are shown as mean ± SEM. Statistical analysis performed using an unpaired, 2-tailed Student’s t test. N.S., not significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts